Research
Hormonal
Semaglutide is endorsed as a secondary treatment for improving glycemic control in type 2 diabetes mellitus (T2DM).
Practitioners can consider semaglutide as a secondary option for patients with T2DM to improve blood sugar control.
StrongSupportsmedium confidence
It has been endorsed as a secondary treatment for improving glycemic control in T2DM.
Why this rating
The abstract suggests a strong endorsement for the treatment based on studies.
Source
Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity
Raghav Gupta et al. · Current Signal Transduction Therapy · 2025
DOI 10.2174/0115743624346660250317013032
otherCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →